SUMO1 knockdown reversed PARP1 inhibitors-caused amelioration of cardiac hypertrophy in PE-treated NRCMs, as revealed by the increased protein level of ANF (Figure 7G), increased ANF and BNP mRNA levels (Figure 7H), and the increased cell surface area (Figure 7I). This evidence concerns the gene NPPB and cardiac hypertrophy.